COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer

Table 1 Mass spectrometry identified O-GalNAc modified proteins

Protein	Gene	Uniprot acc. No.	NetOGlyc 4.0	References
Nucleolin	NCL	P19338	+++	[35]
Alpha-1-acid glycoprotein 1	AGP1	P02763	-
Alpha-actinin-4	ACTN4	O43707	+++
Ig alpha-1 chain C	IGHA1	P01876	++
Elongation factor 2	EEF2	P13639	++
GRP-78	HSPA5	P11021	+	[33]
HSP73	HSPA8	P11142	+
PABP1	PABPC1	P11940	++
PABP4	PABPC4	Q13310	+
Alpha-enolase	ENO1	Q6GMP2	+
Elongation factor 1-gamma	EEF1G	P26641	++
EF-1-alpha-like 3	EEF1A1P5	Q5VTE0	+
Tubulin beta	TUBB2A	Q13885	-
Galectin-12	LGALS12	Q96DT0	++
Ras association domain-containing protein 2	RASSF2	P50749	+++
GAPDH	GAPDH	P04406	+
Nucleophosmin	NPM1	Q8WTW5	+++
Annexin A2	ANXA2	P07355	+
37 kDa laminin receptor precursor	RPSA	Q86VC0	+++
Leucyl-cystinyl aminopeptidase	LNPEP	Q9UIQ6	+
eIF-5B	EIF5B	O60841	+++
Armadillo repeat-containing protein 4	ARMC4	Q5T2S8	+++
LanC-like protein 2	LANCL2	Q9NS86	++

Proteins identified from Panc-1 COSMC knockdown cells by immunoprecipitation using VVL agarose accompanied by mass spectrometry. The O-GalNAc prediction tool (NetOGlyc 4.0) [52] was used to assess possibility of O-glycosylation. Score indicates percentage of possibly O-GalNAc modified Serin/Threonin residues (+ <10 %, ++ <20 %, +++ > 20 %). References are presented for previously identified O-GalNAc modified glycoproteins

ISSN: 1476-4598